Clinical Trial

Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Study acronym: MAV-RAPA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM). Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2014-01-20; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2014-12-02
Trial Details
NCT Number NCT02042326
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Conditions Arteriovenous Malformations
Enrollment 50 participants
Start Date 2014-09-12
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-13